Sage Therapeutics has said it will cut its headcount by 40% in the wake of the narrower-than-hoped approval of its flagship antidepressant Zurzuvae by the FDA, with two of the company's founders ...

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Sage Therapeutics (NASDAQ:SAGE) announced a reorganization, including a workforce reduction of about 33%, to support the ongoing launch of ZURZUVAE for postpartum depression and to focus on ...

The setbacks include disappointing clinical trial results, a reduced US Food and Drug Administration (FDA) approval for its ...

The GABAA receptor positive allosteric modulator will be sold as Zurzuvae for PPD, which affects women after childbirth and can make it hard for new mothers to bond with their newborns.